Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 33INDUSTRY 13NETWORK 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 44Vincristine 37Radiotherapy 30Radiation 30Cisplatin 30Carboplatin 29Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Platinum 15Gemcitabine 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 141,2-diaminocyclohexaneplatinum II citrate 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Pluvicto × 1 year × Clear all
NCT06783348 2026-06-04

RENALUT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Recruiting
48 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡